[FG] Kappos Ludwig

Martina, Greselin et al. (2025) ‘AI-assisted identification of disability patterns within identical EDSS grades’, Mult Scler ., 31(6), pp. 677–688. Available at: https://doi.org/10.1177/13524585251327300.

Kappos, Ludwig et al. (2025) ‘Composite Confirmed Disability Worsening/Progression Is a Useful Clinical Endpoint for Multiple Sclerosis Clinical Trials’, Neurology, 104(10). Available at: https://doi.org/10.1212/wnl.0000000000213558.

Géraldine, Androdias et al. (2025) ‘De-escalating and discontinuing disease-modifying therapies in multiple sclerosis’, Brain, 148(5), pp. 1459–1478. Available at: https://doi.org/10.1093/brain/awae409.

Özgür, Yaldizli et al. (2025) ‘Personalized treatment decision algorithms for the clinical application of serum neurofilament light chain in multiple sclerosis: A modified Delphi Study’, Mult Scler . [Preprint]. Available at: https://doi.org/10.1177/13524585251335466 .

Mario, Ocampo-Pineda et al. (2025) ‘White Matter Tract Degeneration in Multiple Sclerosis Patients With Progression Independent of Relapse Activity’, Neurol Neuroimmunol Neuroinflamm . , 12(3), p. e200388. Available at: https://doi.org/10.1212/NXI.0000000000200388.

Ocampo-Pineda, M. et al. (2025) ‘White Matter Tract Degeneration in Multiple Sclerosis Patients With Progression Independent of Relapse Activity’, Neurology: Neuroimmunology and NeuroInflammation, 12(3). Available at: https://doi.org/10.1212/NXI.0000000000200388.

Jannis, Müller et al. (2025) ‘Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis’, JAMA Neurol . , p. e250495. Available at: https://doi.org/10.1001/jamaneurol.2025.0495.

Riccardo, Galbusera et al. (2025) ‘Quantitative T1 is sensitive to cortical remyelination in multiple sclerosis: A postmortem MRI study’, Brain Pathol ., p. e70010. Available at: https://doi.org/10.1111/bpa.70010.

Mallucci, Giulia et al. (2025) ‘Neurostatus-SMARTCARE clinical trial: Enabling health care professionals to assess EDSS for decentralized trials in multiple sclerosis’, Multiple Sclerosis Journal, 31(4), pp. 497–501. Available at: https://doi.org/10.1177/13524585241305966.

Müller, Jannis et al. (2025) ‘Treatment De-escalation in Relapsing-Remitting Multiple Sclerosis: An Observational Study’, CNS Drugs, 39, pp. 403–416. Available at: https://doi.org/10.1007/s40263-025-01164-w.

Brunner, Eveline et al. (2025) ‘Atherosclerosis in patients with cervical artery dissection’, European Stroke Journal, 10(1), pp. 198–205. Available at: https://doi.org/10.1177/23969873241274547.

Giulio, Disanto et al. (2025) ‘Treatment persistence and clinical outcomes in patients starting B cell depleting therapies within the Swiss MS Cohort’, Mult Scler J Exp Transl Clin ., 11(1), p. 20552173251315457. Available at: https://doi.org/10.1177/20552173251315457.

Jannis, Müller et al. (2025) ‘Treatment De-escalation in Relapsing-Remitting Multiple Sclerosis: An Observational Study’, CNS Drugs ., 39(4), pp. 403–416. Available at: https://doi.org/10.1007/s40263-025-01164-w.

Ralph, Hb Benedict et al. (2025) ‘Cognitive effects of ocrelizumab vs interferon β-1a in relapsing multiple sclerosis: A post hoc analysis of the OPERA I/II trials’, Mult Scler Relat Disord . [Preprint]. Available at: https://doi.org/10.1016/j.msard.2025.106310.

Paolo A, Muraro et al. (2025) ‘Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis and neuromyelitis optica spectrum disorder - recommendations from ECTRIMS and the EBMT’, Nat Rev Neurol . , 21(3), pp. 140–158. Available at: https://doi.org/10.1038/s41582-024-01050-x.

Silvan, Pless et al. (2025) ‘CoGames: Development of an adaptive smartphone-based and gamified monitoring tool for cognitive function in Multiple Sclerosis’, J Neurol . , 272(2), p. 119. Available at: https://doi.org/doi: 10.1007/s00415-024-12818-y.

Patrick, Vermersch et al. (2025) ‘Effect of siponimod on retinal thickness, a marker of neurodegeneration, in participants with SPMS: Findings from the EXPAND OCT substudy’, Mult Scler Relat Disord . , 94, p. 106259. Available at: https://doi.org/10.1016/j.msard.2025.106259.

Oechtering, Johanna et al. (2025) ‘Aberrant Complement Activation Is Associated With Structural Brain Damage in Multiple Sclerosis’, Neurology: Neuroimmunology and NeuroInflammation, 12(2). Available at: https://doi.org/10.1212/nxi.0000000000200361.

Benkert, Pascal et al. (2025) ‘Serum Glial Fibrillary Acidic Protein and Neurofilament Light Chain Levels Reflect Different Mechanisms of Disease Progression under B-Cell Depleting Treatment in Multiple Sclerosis’, Annals of Neurology, 97(1), pp. 104–115. Available at: https://doi.org/10.1002/ana.27096.

Damiano, Marastoni et al. (2025) ‘Intrathecal Inflammatory Profile and Gray Matter Damage Predict Progression Independent of Relapse Activity in Early Multiple Sclerosis’, Neurol Neuroimmunol Neuroinflamm . 01.05.2025, 12(4), p. e200399. Available at: https://doi.org/10.1212/NXI.0000000000200399.

Douglas L, Arnold et al. (2025) ‘Short- and long-term effects of early versus delayed treatment with ocrelizumab on cerebellar volume loss in patients with RMS and PPMS’, Mult Scler . [Preprint]. Available at: https://doi.org/10.1177/13524585251325086.

Müller, Jannis et al. (2025) ‘Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis’, JAMA Neurology [Preprint]. Available at: https://doi.org/10.1001/jamaneurol.2025.0495.

Pontillo, G. et al. (2025) ‘More Than the Sum of Its Parts: Disrupted Core Periphery of Multiplex Brain Networks in Multiple Sclerosis’, Human Brain Mapping, 46(1). Available at: https://doi.org/10.1002/hbm.70107.

Sanabria-Diaz, Gretel et al. (2025) ‘Advanced MRI Measures of Myelin and Axon Volume Identify Repair in Multiple Sclerosis’, Annals of Neurology, 97(1), pp. 134–148. Available at: https://doi.org/10.1002/ana.27102.

Gomes, Ana Beatriz Ayroza Galvão Ribeiro et al. (2024) ‘Neurofilament Light Chain as a Discriminator of Disease Activity Status in MOG Antibody-Associated Disease’, Neurology: Neuroimmunology and NeuroInflammation, 12(1). Available at: https://doi.org/10.1212/NXI.0000000000200347.

Barakovic, Muhamed et al. (2024) ‘A novel imaging marker of cortical “cellularity” in multiple sclerosis patients’, Scientific Reports, 14(1). Available at: https://doi.org/10.1038/s41598-024-60497-6.

Janiaud, Perrine et al. (2024) ‘MultiSCRIPT-Cycle 1—a pragmatic trial embedded within the Swiss Multiple Sclerosis Cohort (SMSC) on neurofilament light chain monitoring to inform personalized treatment decisions in multiple sclerosis: a study protocol for a randomized clinical trial’, Trials, 25(1). Available at: https://doi.org/10.1186/s13063-024-08454-6.

Oh, J. et al. (2024) ‘Use of smartphone-based remote assessments of multiple sclerosis in Floodlight Open, a global, prospective, open-access study’, Scientific Reports, 14(1). Available at: https://doi.org/10.1038/s41598-023-49299-4.

Zietz, Annaelle et al. (2024) ‘Enhancement of STroke REhabilitation with Levodopa (ESTREL): Rationale and design of a randomized placebo-controlled, double blind superiority trial’, European Stroke Journal, 9(4), pp. 1093–1102. Available at: https://doi.org/10.1177/23969873241255867.

Pontillo, Giuseppe et al. (2024) ‘Disentangling Neurodegeneration From Aging in Multiple Sclerosis Using Deep Learning: The Brain-Predicted Disease Duration Gap’, Neurology, 103(10). Available at: https://doi.org/10.1212/WNL.0000000000209976.

Woelfle, Tim et al. (2024) ‘Benchmarking Human–AI collaboration for common evidence appraisal tools’, Journal of Clinical Epidemiology. 12.09.2024, 175. Available at: https://doi.org/10.1016/j.jclinepi.2024.111533.

Geraldes, R. et al. (2024) ‘The influence of MOGAD on diagnosis of multiple sclerosis using MRI’, Nature Reviews Neurology, 20(10), pp. 620–635. Available at: https://doi.org/10.1038/s41582-024-01005-2.

Cagol, Alessandro et al. (2024) ‘Advanced Quantitative MRI Unveils Microstructural Thalamic Changes Reflecting Disease Progression in Multiple Sclerosis’, Neurology: Neuroimmunology and NeuroInflammation, 11(6). Available at: https://doi.org/10.1212/NXI.0000000000200299.

Müller, Jannis et al. (2024) ‘Quantifying Remyelination Using χ-Separation in White Matter and Cortical Multiple Sclerosis Lesions’, Neurology, 103(6). Available at: https://doi.org/10.1212/WNL.0000000000209604.

Cortese, Rosa et al. (2024) ‘Grey Matter Atrophy and its Relationship with White Matter Lesions in Patients with Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease, Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder, and Multiple Sclerosis’, Annals of Neurology, 96(2), pp. 276–288. Available at: https://doi.org/10.1002/ana.26951.

Greselin, Martina et al. (2024) ‘Contrast-Enhancing Lesion Segmentation in Multiple Sclerosis: A Deep Learning Approach Validated in a Multicentric Cohort’, Bioengineering, 11(8), p. 858. Available at: https://doi.org/10.3390/bioengineering11080858.

Sastre-Garriga, J. et al. (2024) ‘Value of Optic Nerve MRI in Multiple Sclerosis Clinical Management: A MAGNIMS Position Paper and Future Perspectives’, Neurology, 103(3). Available at: https://doi.org/10.1212/wnl.0000000000209677.

Kappos, L. et al. (2024) ‘Long-term clinical outcomes in patients with CIS treated with interferon beta-1b: results from the 15-year follow up of the BENEFIT trial’, Journal of Neurology, 271(7), pp. 4599–4609. Available at: https://doi.org/10.1007/s00415-024-12417-x.

Ciccarelli, O. et al. (2024) ‘Using the Progression Independent of Relapse Activity Framework to Unveil the Pathobiological Foundations of Multiple Sclerosis’, Neurology, 103(1). Available at: https://doi.org/10.1212/WNL.0000000000209444.

Kaufmann, Josefin E. et al. (2024) ‘Antithrombotic Treatment for Cervical Artery Dissection: A Systematic Review and Individual Patient Data Meta-Analysis’, JAMA Neurology. 13.05.2024, 81(6), pp. 630–637. Available at: https://doi.org/10.1001/jamaneurol.2024.1141.

Chitnis, T. et al. (2024) ‘Teriflunomide in pediatric patients with relapsing multiple sclerosis: Open-label extension of TERIKIDS’, Multiple Sclerosis Journal, 30(7), pp. 833–842. Available at: https://doi.org/10.1177/13524585241242050.

Diem, L et al. (2024) ‘Efficacy and safety of ocrelizumab in patients with relapsing multiple sclerosis: Real-world experience of two Swiss multiple sclerosis centers’, Multiple Sclerosis and Related Disorders, 86. Available at: https://doi.org/10.1016/j.msard.2024.105570.

Hirt, Julian et al. (2024) ‘Clinical trial evidence of quality-of-life effects of disease-modifying therapies for multiple sclerosis: a systematic analysis’, Journal of Neurology, 271(6), pp. 3131–3141. Available at: https://doi.org/10.1007/s00415-024-12366-5.

Wendebourg, Maria Janina et al. (2024) ‘Cervical and thoracic spinal cord gray matter atrophy is associated with disability in patients with amyotrophic lateral sclerosis’, European Journal of Neurology, 31(6). Available at: https://doi.org/10.1111/ene.16268.

Kaufmann, Josefin E. et al. (2024) ‘Toward Individual Treatment in Cervical Artery Dissection: Subgroup Analysis of the TREAT-CAD Randomized Trial’, Annals of Neurology. 16.02.2024, 95(5), pp. 886–897. Available at: https://doi.org/10.1002/ana.26886.

Khalil, Michael et al. (2024) ‘Neurofilaments as biomarkers in neurological disorders — towards clinical application’, Nature Reviews Neurology, 20(5), pp. 269–287. Available at: https://doi.org/10.1038/s41582-024-00955-x.

Papadopoulou, Athina et al. (2024) ‘Visual evoked potentials in multiple sclerosis: P100 latency and visual pathway damage including the lateral geniculate nucleus’, Clinical Neurophysiology. 20.02.2024, 161, pp. 122–132. Available at: https://doi.org/10.1016/j.clinph.2024.02.020.

Fox, R.J. et al. (2024) ‘Temporal Relationship between Serum Neurofilament Light Chain and Radiologic Disease Activity in Patients with Multiple Sclerosis’, Neurology, 102(9). Available at: https://doi.org/10.1212/WNL.0000000000209357.

Woelfle, Tim et al. (2024) ‘Benchmarking Human-AI Collaboration for Common Evidence Appraisal Tools’, medRxiv [Preprint]. Cold Spring Harbor Laboratory (medRxiv). Available at: https://doi.org/10.1101/2024.04.21.24306137.

Weigel, M. et al. (2024) ‘Cerebellar Ex Vivo Magnetic Resonance Imaging at its Feasibility Limit: Up to 77-Microns Isotropic Resolution using Low-Bandwidth Balanced Steady State Free Precession (LoBa-bSSFP) Sequences and 3T Standard Equipment’. Cold Spring Harbor Laboratory. Available at: https://doi.org/10.1101/2024.04.18.589707.

Hirt, Julian et al. (2024) ‘Use of pragmatic randomized trials in multiple sclerosis: A systematic overview’, Multiple Sclerosis Journal, 30(4-5), pp. 463–478. Available at: https://doi.org/10.1177/13524585231221938.

Lazzarotto, A. et al. (2024) ‘Time is myelin: early cortical myelin repair prevents atrophy and clinical progression in multiple sclerosis’, Brain, 147(4), pp. 1331–1343. Available at: https://doi.org/10.1093/brain/awae024.

Janiaud, Perrine et al. (2024) ‘MultiSCRIPT-Cycle 1- A Pragmatic trial embedded within the Swiss Multiple Sclerosis Cohort (SMSC) on neurofilament light chain monitoring to inform personalized treatment decisions in Multiple Sclerosis: a study protocol for a randomized clinical trial’, medRxiv [Preprint]. Cold Spring Harbor Laboratory (medRxiv). Available at: https://doi.org/10.1101/2024.03.22.24304720.

Callegari, Ilaria et al. (2024) ‘Cell-binding IgM in CSF is distinctive of multiple sclerosis and targets the iron transporter SCARA5’, Brain, 147(3), pp. 839–848. Available at: https://doi.org/10.1093/brain/awad424.

Gloor M et al. (2024) ‘Longitudinal analysis of new multiple sclerosis lesions with magnetization transfer and diffusion tensor imaging’, European Radiology. 02.09.2023, 34(3), pp. 1680–1691. Available at: https://doi.org/10.1007/s00330-023-10173-6.

Oechtering, Johanna et al. (2024) ‘Complement Activation Is Associated With Disease Severity in Multiple Sclerosis’, Neurology: Neuroimmunology and NeuroInflammation, 11(2). Available at: https://doi.org/10.1212/NXI.0000000000200212.

Cagol, Alessandro et al. (2024) ‘Diagnostic Performance of Cortical Lesions and the Central Vein Sign in Multiple Sclerosis’, JAMA Neurology, 81(2), pp. 143–153. Available at: https://doi.org/10.1001/jamaneurol.2023.4737.

Kappos, Ludwig et al. (2024) ‘Ocrelizumab exposure in relapsing–remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension’, Journal of Neurology, 271(2), pp. 642–657. Available at: https://doi.org/10.1007/s00415-023-11943-4.

Cagol, Alessandro et al. (2024) ‘Association of Spinal Cord Atrophy and Brain Paramagnetic Rim Lesions With Progression Independent of Relapse Activity in People With MS’, Neurology, 102(1). Available at: https://doi.org/10.1212/WNL.0000000000207768.

Cagol, Alessandro et al. (2024) ‘Association of Spinal Cord Atrophy and Brain Paramagnetic Rim Lesions With Progression Independent of Relapse Activity in People With MS’, Neurology, 102(1). Available at: https://doi.org/10.1212/wnl.0000000000207768.

Cagol, Alessandro et al. (2024) ‘Association of Spinal Cord Atrophy and Brain Paramagnetic Rim Lesions With Progression Independent of Relapse Activity in People With MS’, Neurology, 102(1). Available at: https://doi.org/10.1212/wnl.0000000000207768.

Wilson, David et al. (2024) ‘Development and multi-center validation of a fully automated digital immunoassay for neurofilament light chain: toward a clinical blood test for neuronal injury’, Clinical Chemistry and Laboratory Medicine, 62(2), pp. 322–331. Available at: https://doi.org/10.1515/cclm-2023-0518.

Derfuss, T. et al. (2024) ‘Long-term analysis of infections and associated risk factors in patients with multiple sclerosis treated with ocrelizumab: pooled analysis of 13 interventional clinical trials’, Therapeutic Advances in Neurological Disorders, 17. Available at: https://doi.org/10.1177/17562864241277736.

Filioglo, Andrei et al. (2024) ‘Corrigendum: Tandem occlusions involving the internal carotid and anterior cerebral arteries—A rare form of stroke: results from the multicenter EVATRISP collaboration study (Frontiers in Neurology, (2022), 13, (1024891), 10.3389/fneur.2022.1024891)’, Frontiers in Neurology , 15. Available at: https://doi.org/10.3389/fneur.2024.1450372.

Lorscheider, Johannes et al. (2024) ‘Disease-modifying treatment and disability progression in subclasses of patients with primary progressive MS: results from the Big MS Data Network’, Journal of Neurology, Neurosurgery and Psychiatry, pp. jnnp–2024–334700. Available at: https://doi.org/10.1136/jnnp-2024-334700.

Nybondas, Miranda et al. (2024) ‘Intravenous thrombolysis in young adults with ischemic stroke: A cohort study from the international TRISP collaboration’, European Stroke Journal [Preprint]. Available at: https://doi.org/10.1177/23969873241304305.

Riegler, Christoph et al. (2024) ‘Endovascular therapy in patients with acute intracranial non-terminal internal carotid artery occlusion (ICA-I)’, European Stroke Journal [Preprint]. Available at: https://doi.org/10.1177/23969873241278948.

Steinegger, L. et al. (2024) ‘Acute leukoencephalopathy associated with daratumumab treatment in POEMS syndrome: a case report’, Frontiers in Immunology, 15. Available at: https://doi.org/10.3389/fimmu.2024.1451693.

Wali, Nabila et al. (2024) ‘Endovascular treatment in patients with acute ischemic stroke presenting beyond 6 h after symptom onset: An international multicenter cohort study of the EVA-TRISP collaboration’, European Stroke Journal [Preprint]. Available at: https://doi.org/10.1177/23969873241277437.

Abdelhak, Ahmed et al. (2023) ‘Neurofilament Light Chain Elevation and Disability Progression in Multiple Sclerosis’, JAMA Neurology, 80(12), pp. 1317–1325. Available at: https://doi.org/10.1001/jamaneurol.2023.3997.

Abdelhak, Ahmed et al. (2023) ‘Neurofilament Light Chain Elevation and Disability Progression in Multiple Sclerosis’, JAMA Neurology, 80(12), pp. 1317–1325. Available at: https://doi.org/10.1001/jamaneurol.2023.3997.

Baumgartner P et al. (2023) ‘Safety and effectiveness of IV Thrombolysis in retinal artery occlusion: A multicenter retrospective cohort study’, European Stroke Journal, 8(4), pp. 966–973. Available at: https://doi.org/10.1177/23969873231185895.

Diouf I et al. (2023) ‘Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: Causal inference to emulate a multiarm randomised trial’, Journal of Neurology, Neurosurgery and Psychiatry, 94(12), pp. 1004–1011. Available at: https://doi.org/10.1136/jnnp-2023-331499.

Hauser, S.L. et al. (2023) ‘Safety of Ocrelizumab in Multiple Sclerosis: Updated Analysis in Patients with Relapsing and Primary Progressive Multiple Sclerosis’, in Multiple Sclerosis and Related Disorders. Elsevier B.V. (Multiple Sclerosis and Related Disorders). Available at: https://doi.org/10.1016/j.msard.2023.105308.

Montalban, X. et al. (2023) ‘Design and Baseline Characteristics of Phase 3, Double-Blind, Randomised Trials Evaluating the Efficacy and Safety of Evobrutinib Versus Teriflunomide in Relapsing Multiple Sclerosis (evolutionRMS 1 and 2)’. Elsevier B.V., 80. Available at: https://doi.org/10.1016/j.msard.2023.105328.

Woelfle, Tim et al. (2023) ‘Smartwatch-derived sleep and heart rate measures complement step counts in explaining established metrics of MS severity’, Multiple Sclerosis and Related Disorders, 80. Available at: https://doi.org/10.1016/j.msard.2023.105104.

Müller, Jannis et al. (2023) ‘Harmonizing Definitions for Progression Independent of Relapse Activity inMultiple Sclerosis A Systematic Review’, JAMA Neurology, 80(11), pp. 1232–1245. Available at: https://doi.org/10.1001/jamaneurol.2023.3331.

Müller, Jannis et al. (2023) ‘Harmonizing Definitions for Progression Independent of Relapse Activity inMultiple Sclerosis A Systematic Review’, JAMA Neurology, 80(11), pp. 1232–1245. Available at: https://doi.org/10.1001/jamaneurol.2023.3331.

Callegari, I. et al. (2023) ‘Cell-binding IgM in CSF is distinctive of multiple sclerosis and targets the iron transporter SCARA5’. Cold Spring Harbor Laboratory. Available at: https://doi.org/10.1101/2023.09.29.560121.

Hauser S.L. et al. (2023) ‘The Development of Ofatumumab, a Fully Human Anti-CD20 Monoclonal Antibody for Practical Use in Relapsing Multiple Sclerosis Treatment’, Neurology and Therapy, 12(5), pp. 1491–1515. Available at: https://doi.org/10.1007/s40120-023-00518-0.

Seystahl K et al. (2023) ‘IV Thrombolysis With or Without Endovascular Treatment for Suspected Ischemic Stroke in Patients With Intracranial Tumors’, Neurology, 101(12), pp. E1241–E1255. Available at: https://doi.org/10.1212/WNL.0000000000207624.

Harding-Forrester, Sam et al. (2023) ‘Disability accrual in primary and secondary progressive multiple sclerosis’, Journal of Neurology, Neurosurgery and Psychiatry, 94(9), pp. 707–717. Available at: https://doi.org/10.1136/jnnp-2022-330726.

Todea, Alexandra Ramona et al. (2023) ‘A Multicenter Longitudinal MRI Study Assessing LeMan-PV Software Accuracy in the Detection of White Matter Lesions in Multiple Sclerosis Patients’, Journal of Magnetic Resonance Imaging, 58(3), pp. 864–876. Available at: https://doi.org/10.1002/jmri.28618.

Altersberger, Valerian L. et al. (2023) ‘Intravenous Thrombolysis 4.5–9 Hours After Stroke Onset: A Cohort Study from the TRISP Collaboration’, Annals of Neurology. 28.04.2023, 94(2), pp. 309–320. Available at: https://doi.org/10.1002/ana.26669.

Bar-Or, Amit et al. (2023) ‘Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials’, eBioMedicine, 93. Available at: https://doi.org/10.1016/j.ebiom.2023.104662.

Pless S et al. (2023) ‘Assessment of cognitive performance in multiple sclerosis using smartphone-based training games: a feasibility study’, Journal of Neurology, 270(7), pp. 3451–3463. Available at: https://doi.org/10.1007/s00415-023-11671-9.

Cortese R. et al. (2023) ‘Clinical and MRI measures to identify non-acute MOG-antibody disease in adults’, Brain, 146(6), pp. 2489–2501. Available at: https://doi.org/10.1093/brain/awac480.

Dittrich, Tolga D et al. (2023) ‘Apical pulmonary lesions suspected of malignancy visible on neck CT angiography performed for acute stroke: Prevalence, treatment, and clinical implications – the PLEURA study’, European Stroke Journal, 8(2), pp. 549–556. Available at: https://doi.org/10.1177/23969873231151488.

Traenka, Christopher et al. (2023) ‘Recanalization Therapies for Large Vessel Occlusion Due to Cervical Artery Dissection: A Cohort Study of the EVA-TRISP Collaboration’, Journal of Stroke, 25(2), pp. 272–281. Available at: https://doi.org/10.5853/jos.2022.03370.

Tsagkas, Charidimos et al. (2023) ‘Anterior horn atrophy in the cervical spinal cord: A new biomarker in progressive multiple sclerosis’, Multiple Sclerosis Journal, 29(6), pp. 702–718. Available at: https://doi.org/10.1177/13524585221139152.

Pfeuffer S. et al. (2023) ‘Effect of Previous Disease-Modifying Therapy on Treatment Effectiveness for Patients Treated With Ocrelizumab’, Neurology: Neuroimmunology and NeuroInflammation, 10(3). Available at: https://doi.org/10.1212/NXI.0000000000200104.

Agosti, Reto et al. (2023) ‘Prevalence and Burden of Migraine in Switzerland: Cross-Sectional Study in ten Specialised Headache Centres from the BECOME Study’, Pain and Therapy, 12(2), pp. 575–591. Available at: https://doi.org/10.1007/s40122-023-00484-3.

Cagol A et al. (2023) ‘Optical coherence tomography reflects clinically relevant gray matter damage in patients with multiple sclerosis’, Journal of Neurology, 270(4), pp. 2139–2148. Available at: https://doi.org/10.1007/s00415-022-11535-8.

Diouf I. et al. (2023) ‘Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis’, European Journal of Neurology, 30(4), pp. 1014–1024. Available at: https://doi.org/10.1111/ene.15706.

Vrenken H. et al. (2023) ‘Temporal evolution of new T1-weighted hypo-intense lesions and central brain atrophy in patients with a first clinical demyelinating event treated with subcutaneous interferon β-1a’, Journal of Neurology, 270(4), pp. 2271–2282. Available at: https://doi.org/10.1007/s00415-022-11554-5.

Hauser S.L. et al. (2023) ‘Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis’, Neurology: Neuroimmunology and NeuroInflammation, 10(2). Available at: https://doi.org/10.1212/NXI.0000000000200094.

Meinel, Thomas R. et al. (2023) ‘Intravenous Thrombolysis in Patients With Ischemic Stroke and Recent Ingestion of Direct Oral Anticoagulants’, JAMA Neurology, 80(3), pp. 233–243. Available at: https://doi.org/10.1001/jamaneurol.2022.4782.

Al-Ajlan FS et al. (2023) ‘Time Course of Early Hematoma Expansion in Acute Spot-Sign Positive Intracerebral Hemorrhage: Prespecified Analysis of the SPOTLIGHT Randomized Clinical Trial’, Stroke, 54(3), pp. 715–721. Available at: https://doi.org/10.1161/STROKEAHA.121.038475.

Bakker, M.K. et al. (2023) ‘Genetic Risk Score for Intracranial Aneurysms: Prediction of Subarachnoid Hemorrhage and Role in Clinical Heterogeneity’, Stroke, 54(3), pp. 810–818. Available at: https://doi.org/10.1161/STROKEAHA.122.040715.

Dittrich, Tolga D. et al. (2023) ‘Mechanical Thrombectomy Versus Best Medical Treatment in the Late Time Window in Non-DEFUSE-Non-DAWN Patients: A Multicenter Cohort Study’, Stroke, 54(3), pp. 722–730. Available at: https://doi.org/10.1161/STROKEAHA.122.039793.